Sarcoma News

PD-1 targeted therapy plus metronomic chemotherapy induced limited responses in patients with soft tissue sarcoma or gastrointestinal stromal tumors, according to data from a phase 2 clinical trial published in JAMA Oncology.

Whole-body MRI increased detection of abnormalities and new cancers in patients with Li-Fraumeni syndrome, according to results of two studies published in JAMA Oncology.

Patients with advanced cancer who arrived at the ED with delirium had increased rates of hospitalization and ICU admissions, as well as shorter survival rates, according to a study published in The Oncologist.

Patients with advanced cancer had significantly lower survival rates following in-hospital cardiac arrest than those without advanced cancer, according to a retrospective study published in Journal of Oncology Practice.

Four leading national cancer organizations have united in their mission to reduce the number of health disparities in the United States and to ensure all patients, regardless of social demographics and socioeconomic status, benefit from cancer research, according to a joint position statement published in Journal of Clinical Oncology.

NCI and the Children’s Oncology Group today announced enrollment opened for a phase 2 study designed to evaluate targeted therapies in children and adolescents with solid tumors.

ASCO today issued a position statement that proposes a wide range of cost-cutting strategies that can be tested to help lower drug costs based on a standard definition of value.

The FDA has taken several actions in the past week related to oncology treatments.

The FDA granted orphan drug designation to entrectinib for the treatment of patients with NTRK fusion–positive solid tumors, according to the drug’s manufacturer.

Click here to read the Cover Story, “Deeper understanding of disease biology may expand sarcoma treatment options.”